{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:34:25Z","timestamp":1769240065668,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Care Clinics"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.ccc.2010.07.003","type":"journal-article","created":{"date-parts":[[2010,10,21]],"date-time":"2010-10-21T09:32:30Z","timestamp":1287653550000},"page":"679-688","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacotherapy in the Critically Ill Obese Patient"],"prefix":"10.1016","volume":"26","author":[{"given":"Charles J.","family":"Medico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccc.2010.07.003_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00003088-199325020-00003","article-title":"Clinical pharmacokinetics of drugs in obesity: an update","volume":"25","author":"Cheymol","year":"1993","journal-title":"Clin Pharm"},{"key":"10.1016\/j.ccc.2010.07.003_bib2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0002-9343(88)90310-5","article-title":"Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass","volume":"84","author":"Salazar","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.ccc.2010.07.003_bib3","first-page":"57","article-title":"Increased glomerular filtration rate and adrenocortical function in obese women","volume":"4","author":"Stockholm","year":"1980","journal-title":"Int J Obes"},{"key":"10.1016\/j.ccc.2010.07.003_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2165\/00003088-198207020-00002","article-title":"Pharmacokinetics of drugs in obesity","volume":"7","author":"Abernethy","year":"1982","journal-title":"Clin Pharm"},{"key":"10.1016\/j.ccc.2010.07.003_bib5","first-page":"706","article-title":"Influence of obesity on drug disposition","volume":"6","author":"Blouin","year":"1987","journal-title":"Clin Pharm"},{"issue":"5","key":"10.1016\/j.ccc.2010.07.003_bib6","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1227\/01.NEU.0000347090.22818.35","article-title":"Cost effectiveness of a clinical pharmacist on a neurosurgical team","volume":"65","author":"Weant","year":"2009","journal-title":"Neurosurgery"},{"issue":"7","key":"10.1016\/j.ccc.2010.07.003_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1592\/phco.29.7.761","article-title":"Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with thromboembolic or infarction-related events","volume":"29","author":"MacLaren","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.ccc.2010.07.003_bib8","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/00003246-199406000-00027","article-title":"Impact of a clinical pharmacist in a multidisciplinary intensive care unit","volume":"22","author":"Montazeri","year":"1994","journal-title":"Crit Care Med"},{"issue":"12","key":"10.1016\/j.ccc.2010.07.003_bib9","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1097\/CCM.0b013e31818f2269","article-title":"Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections","volume":"36","author":"MacLaren","year":"2008","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccc.2010.07.003_bib10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.thromres.2009.02.003","article-title":"Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients","volume":"125","author":"Rondina","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.ccc.2010.07.003_bib11","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1538-7836.2007.02565.x","article-title":"Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials","volume":"5","author":"Davidson","year":"2007","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.ccc.2010.07.003_bib12","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.thromres.2008.08.005","article-title":"Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency","volume":"123","author":"Clark","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.ccc.2010.07.003_bib13","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1538-7836.2005.01304.x","article-title":"The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE)","volume":"3","author":"Barba","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"10.1016\/j.ccc.2010.07.003_bib14","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ccc.2010.07.003_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11695-007-9381-y","article-title":"Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin","volume":"18","author":"Rowan","year":"2008","journal-title":"Obes Surg"},{"key":"10.1016\/j.ccc.2010.07.003_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.soard.2007.11.010","article-title":"Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity","volume":"4","author":"Borkgren-Okonek","year":"2008","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.ccc.2010.07.003_bib17","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1007\/s00464-008-9997-6","article-title":"Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery","volume":"22","author":"Simone","year":"2008","journal-title":"Surg Endosc"},{"key":"10.1016\/j.ccc.2010.07.003_bib18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","article-title":"The weight-based heparin dosing nomogram compared with a standard care nomogram","volume":"119","author":"Raschke","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccc.2010.07.003_bib19","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.1992.00400200027006","article-title":"Optimal therapeutic level of heparin therapy in patients with venous thrombosis","volume":"152","author":"Hull","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ccc.2010.07.003_bib20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJM198610303151801","article-title":"Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis","volume":"315","author":"Hull","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccc.2010.07.003_bib21","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/ajhp\/58.22.2143","article-title":"Achievement of anticoagulation by using weight based heparin dosing protocol for obese and non-obese patients","volume":"15","author":"Spruill","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ccc.2010.07.003_bib22","first-page":"65","article-title":"Calculation of heparin dosage in a morbidly obese woman","volume":"8","author":"Ellison","year":"1989","journal-title":"Clin Pharm"},{"key":"10.1016\/j.ccc.2010.07.003_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/ajhp\/55.2.159","article-title":"Optimal weight base for a weight-based heparin dosing protocol","volume":"55","author":"Yee","year":"1998","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ccc.2010.07.003_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1345\/aph.1E300","article-title":"Use of a modified dosing weight for heparin therapy in a morbidly obese patient","volume":"39","author":"Schwiesow","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.ccc.2010.07.003_bib25","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4065\/mcp.2009.0220","article-title":"Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight based dosing of unfractionated heparin: a retrospective cohort study","volume":"84","author":"Bauer","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ccc.2010.07.003_bib26","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/01.CIR.0000077530.53367.E9","article-title":"Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin","volume":"107","author":"Anand","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccc.2010.07.003_bib27","doi-asserted-by":"crossref","first-page":"105e","DOI":"10.1592\/phco.30.3.324","article-title":"Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature","volume":"30","author":"Myzienski","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ccc.2010.07.003_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1381\/0960892041590944","article-title":"An approach to venous thromboembolism prophylaxis in laparoscopic roux-en-y gastric bypass surgery","volume":"14","author":"Miller","year":"2004","journal-title":"Obes Surg"},{"issue":"6","key":"10.1016\/j.ccc.2010.07.003_bib29","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ccc.2010.07.003_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccc.2010.07.003_bib31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1345\/aph.1E386","article-title":"Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis","volume":"39","author":"Levy","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ccc.2010.07.003_bib32","series-title":"Argatroban [package insert]","year":"2005"},{"key":"10.1016\/j.ccc.2010.07.003_bib33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270004267651","article-title":"Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIb\/IIIa receptor antagonist in patients undergoing percutaneous coronary intervention","volume":"44","author":"Cox","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ccc.2010.07.003_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11239-007-0051-7","article-title":"Effect of body mass index on argatroban therapy during percutaneous coronary intervention","volume":"25","author":"Hursting","year":"2008","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.ccc.2010.07.003_bib35","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1177\/0091270007302951","article-title":"Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia","volume":"47","author":"Rice","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ccc.2010.07.003_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1345\/aph.1L224","article-title":"Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected confirmed heparin-induced thrombocytopenia","volume":"43","author":"Keegan","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ccc.2010.07.003_bib37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.clpt.6100215","article-title":"\u201cGetting the dose right\u201d: facts a blueprint and encouragements","volume":"82","author":"Peck","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ccc.2010.07.003_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00007691-198606000-00011","article-title":"Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects","volume":"8","author":"Yost","year":"1986","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ccc.2010.07.003_bib39","first-page":"750","article-title":"Antibiotic prophylaxis for surgery in morbidly obese patients","volume":"106","author":"Forse","year":"1989","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.ccc.2010.07.003_bib40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1592\/phco.27.8.1081","article-title":"Antimicrobial dosing consideration in obese patients","volume":"27","author":"Manjunath","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ccc.2010.07.003_bib41","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1345\/aph.1K256","article-title":"Serum piperacillin\/tazobactam pharmacokinetics in a morbidly obese individual","volume":"41","author":"Newman","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ccc.2010.07.003_bib42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.ccc.2010.07.003_bib43","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/AAC.50.4.1222-1227.2006","article-title":"Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults","volume":"50","author":"Chen","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2010.07.003_bib44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1345\/aph.1E484","article-title":"Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis","volume":"39","author":"Stein","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ccc.2010.07.003_bib45","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","article-title":"In vivo pharmacodynamics of a new oxazolidinone (linezolid)","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2010.07.003_bib46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/0091270004269562","article-title":"The pharmacokinetics of daptomycin in moderately obese, morbidly obese and matched nonobese subjects","volume":"45","author":"Dvorchik","year":"2005","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ccc.2010.07.003_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1592\/phco.24.1.41.34802","article-title":"Daptomycin","volume":"24","author":"Tedesco","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.ccc.2010.07.003_bib48","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1128\/AAC.00059-07","article-title":"Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin","volume":"51","author":"Manjunath","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2010.07.003_bib49","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/clpt.1993.162","article-title":"Intravenous ciprofloxacin disposition in obesity","volume":"53","author":"Allard","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ccc.2010.07.003_bib50","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/106002809402800622","article-title":"Intravenous ciprofloxacin dosing in morbidly obese patient","volume":"28","author":"Caldwell","year":"1994","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ccc.2010.07.003_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society Health-System pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ccc.2010.07.003_bib52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jclinane.2004.01.009","article-title":"Anesthesia in the obese patient: pharmacokinetic considerations","volume":"17","author":"Casati","year":"2005","journal-title":"J\u00a0Clin Anesth"}],"container-title":["Critical Care Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070410000588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070410000588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T18:20:16Z","timestamp":1559758816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749070410000588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0749070410000588"],"URL":"https:\/\/doi.org\/10.1016\/j.ccc.2010.07.003","relation":{},"ISSN":["0749-0704"],"issn-type":[{"value":"0749-0704","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}